Skip to content

Gulimavu in knee Osteoarthritis

A clinical study to evaluate the effect of leaf of Gulimavu Persea macrantha (Nees.) Kosterm in Sandhigatha vata W.S.R to Osteoarthritis of Knee - GULPERSAN

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011946
Enrollment
30
Registered
2018-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Knee osteoarthritis

Interventions

Intervention1: Persea macrantha TABLETS NO COMPARATOR AGENT: A safe and herbal leaf is used to evaluate the therapeutic efficacy. Formulation - It is a tablet prepared out of only a single drug Persea

Sponsors

SDM Ayurveda Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pateints suffering from sandhigata vata osteoarthritis of knee

Exclusion criteria

Exclusion criteria: Suffering from CHD and IHF Neoplastic and infectious conditions of knee joint

Design outcomes

Primary

MeasureTime frame
Patients relieve from sandhigata vata/ Osteoarthritis of knee signs and symptomsTimepoint: Patients relieve from sandhigata vata/ Osteoarthritis of knee signs and symptoms after 28 days of treatment with follow up at each 7 days

Secondary

MeasureTime frame
Observed that all the patient relieved from the signs and symptoms on treating with the drug for 28 days and patients were free from all the complaints even after stopping of the treatment for 28 days after interventionTimepoint: The scoring was done before and after treatment and statistically proven using Wilcoxan signed rank test. The results shows the study is statistically highly significant.

Countries

India

Contacts

Public ContactDr Niranjan prabhu

Rajiv Gandhi University of Health Sciences

drshrikanth.acharya@gmail.com9449329823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026